key: cord-0967619-u2v3exl4 authors: Bikdeli, Behnood; Chatterjee, Saurav; Arora, Shilpkumar; Monreal, Manuel; Jimenez, David; Krumholz, Harlan M.; Goldhaber, Samuel Z.; Elkind, Mitchell S.V.; Piazza, Gregory title: Cerebral Venous Sinus Thrombosis in the US Population, after Adenovirus-based SARS-CoV-2 Vaccination, and After COVID-19 date: 2021-06-08 journal: J Am Coll Cardiol DOI: 10.1016/j.jacc.2021.06.001 sha: 14670fc8d7f3f6e9817d942aeec2d3224536b987 doc_id: 967619 cord_uid: u2v3exl4 nan Thrombosis has emerged as a major concern in patients with coronavirus disease-2019 . (1, 2) Most recently, thrombotic events, particularly cerebral venous sinus thrombosis (CVST) were reported within days after receiving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) adenovirus-based vaccines.(3) Initially, cases of CVST were reported in close succession to the use of the ChAdOx1 nCoV-19 vaccine (AstraZeneca), mostly in women of childbearing age, with many cases being associated with thrombocytopenia. Subsequently, 6 cases of CVST were reported from the United States with another adenovirusbased vaccine: Ad26.COV2.S vaccine (Johnson & Johnson ), among women of childbearing age. CVST is a rare but potentially devastating disease.(4) Therefore, this issue led to a temporary pause in use of the J&J vaccine in the United States and variable age/sex-based restrictions for the AstraZeneca vaccine in other countries. Herein, we report the rate of CVST associated with these two vaccines based on publicly reported data, versus those occurring after COVID-19, and the estimated incidence rates in the US population. We used the data from The Medicines and Healthcare products Regulatory Agency (from the United Kingdom), 5 and the US Centers for Disease Control and Prevention 6 to report the number of events per vaccinated people with AstraZeneca and Johnson&Johnson vaccines, respectively. We used the data from a multinational study of cerebrovascular events to report CVST rates in hospitalized patients with COVID-19. This study has several limitations. First, we attempted to provide relatively similar follow-up intervals. Nevertheless, the data sources have inherent differences. The AstraZeneca vaccine has not been authorized or used in the United States. Therefore, we report the events based on the data from the MHRA in the United Kingdom. Although some regional variability due to biological, social, or healthcare associated reasons are plausible, within the limits of some variation, the event rates may be relevant to a broad audience. Second, the data from the Nationwide Inpatient Sample indicates the hospitalization rates, rather than incidence. However, most patients with CVST will require hospitalization for the initial stay. Third, the events are subject to underreporting, especially for cases for CVST after vaccination against SARS-CoV-2. The current analyses included updated estimate of these events. As additional events accrue over time, the estimated event rates will be affected. Fourth, we were unable to report event rates per specific age groups, since the numerators and denominators for such analyses are not publicly available from all the four data sources used in this manuscript. Fifth, the surveillance reports from the Centers for Disease Control and Prevention and the Medicines and Healthcare products Regulatory Agency do not provide sufficient details to understand the event rates for CVST associated with thrombocytopenia (so called Vaccine-Induced Thrombotic Thrombocytopenia [VITT]). Sixth, the used to estiimte the CVST event rates in hospitalized patients with COVID-19 may be limited by voluntary inclusion of some hospitals in the registry. ( 7 ) However, the study was multicenter and conducted from several countries. Even if some variation is expected across centers, the magnitude of risk for CVST appears to be several folds higher in hospitalized J o u r n a l P r e -p r o o f patients with COVID-19, than in other groups. Finally, we were not able to report CVST with mRNA-based vaccines. In conclusion, CVST is rare in the general population and after adenovirus-based SARS-CoV-2 vaccination, but appears to be several-fold more common in hospitalized patients with COVID-19. Additional research is required to fully elucidate the event rates, to understand the risk factors for vaccine-associated CVST and to identify strategies to prevent it. In the meantime, transparent realistic communication of the risk estimates will be helpful for shared-decisionmaking between patients and clinicians. J o u r n a l P r e -p r o o f Cardiovascular Medicine Division, Brigham and Women's Hospital Department of Internal Medicine Vagelos College of Physicians and Surgeons, and Department of Epidemiology COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-ofthe-Art Review Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination Cerebral venous thrombosis Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational Registry Date last accessed Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational Registry Endovascular Thrombolysis or Thrombectomy for Cerebral Venous Thrombosis: Study of Nationwide Inpatient Sample 2004-2014